Lomecel-B becomes first cell therapy to receive
Author: Michael
Company’s ‘Immune Refresh’ approach expand
Oxford University analysis finds semaglutide doe
RF Longevity Founder Gary Arendash talks immunit
Company aims to extend female fertility window w
New insights into transcription factors and chro
If approved, HMTM would become the first oral Al
Recent study reveals significant deviations in t
Alamar Bio joins forces with Biomarkers of Aging
Significant Series B funding will enable clinica